Adjuvant Radiotherapy May Have Significant Survival Benefits for Gastric Cancer Patients with 1-29 Lymph Nodes Retrieved

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2022 Feb 4

PMID 35117301

Authors

Siyi Wu

Yuxin Chu

Qinyong Hu

Qibin Song

Affiliations

Soon will be listed here.

Abstract

Background: The role of adjuvant radiotherapy (RT) in gastric cancer (GC) patients has not been well-established. This study initiated a retrospective case-control study to explore the survival impact of adjuvant RT on these patients.

Methods: All patients were collected from the Surveillance, Epidemiology, and End Results (SEER) database. The cohort was assigned into patients without adjuvant RT versus those with adjuvant RT. Descriptive chi-square test was adopted to compare categorical variates between the 2 groups. Kaplan-Meier (KM) method was adopted to estimate the patients' cancer-specific survival (CSS) and overall survival (OS). Cox proportional hazard models were utilized to characterize the prognostic factors of their CSS.

Results: Totally 7,194 patients were recruited in this study, 3,326 (46.2%) patients didn't have RT and 3,868 (53.8%) patients had adjuvant RT. Survival analysis of the entire population showed that adjuvant RT had remarkable survival benefits for the GC patients. The median CSS was 47.0 (42.0-52.0) months in RT group versus 32.0 (29.7-34.3) months in no RT group (P<0.001). Age >60, histologic type 8490, tumor size >50 mm, higher stage TNM, and surgery type 40/50 were independent risk factors for poor prognosis. Comparatively, adjuvant RT and LN examined >0 were independent factors for improving prognosis. Subgroup analysis demonstrated that adjuvant RT had significant survival benefits for patients with 1-14 and 15-29 lymph nodes (LNs) retrieved.

Conclusions: Adjuvant radiotherapy may have significant survival benefits for GC patients with 1-29 LNs retrieved. Our study upholds adjuvant RT for this subset of patients.

References

Picado O, Dygert L, Macedo F, Franceschi D, Sleeman D, Livingstone A . The Role of Surgical Resection for Stage IV Gastric Cancer With Synchronous Hepatic Metastasis. J Surg Res. 2018; 232:422-429. DOI: 10.1016/j.jss.2018.06.067. View

Stumpf P, Amini A, Jones B, Koshy M, Sher D, Lieu C . Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis. Cancer. 2017; 123(17):3402-3409. DOI: 10.1002/cncr.30748. View

Fisher B, Fluck M, Young K, Shabahang M, Blansfield J, Arora T . Urgent Surgery for Gastric Adenocarcinoma: A Study of the National Cancer Database. J Surg Res. 2019; 245:619-628. DOI: 10.1016/j.jss.2019.07.073. View

Woo Y, Goldner B, Ituarte P, Lee B, Melstrom L, Son T . Lymphadenectomy with Optimum of 29 Lymph Nodes Retrieved Associated with Improved Survival in Advanced Gastric Cancer: A 25,000-Patient International Database Study. J Am Coll Surg. 2016; 224(4):546-555. PMC: 5606192. DOI: 10.1016/j.jamcollsurg.2016.12.015. View

Agolli L, Maurizi Enrici R, Osti M . Adjuvant radiochemotherapy for gastric cancer: Should we use prognostic factors to select patients?. World J Gastroenterol. 2016; 22(3):1131-8. PMC: 4716025. DOI: 10.3748/wjg.v22.i3.1131. View

Zhang C, Liu L, Tao F, Guo X, Feng G, Chen F . Bone Metastases Pattern in Newly Diagnosed Metastatic Bladder Cancer: A Population-Based Study. J Cancer. 2018; 9(24):4706-4711. PMC: 6299390. DOI: 10.7150/jca.28706. View

Kim K, Yi B, Lee H, Kang N, Jeung E, Kim S . Stem cells with fused gene expression of cytosine deaminase and interferon-β migrate to human gastric cancer cells and result in synergistic growth inhibition for potential therapeutic use. Int J Oncol. 2011; 40(4):1097-104. PMC: 3584621. DOI: 10.3892/ijo.2011.1288. View

Peng J, Wei Y, Zhou F, Dai J, Zhong Y, Xie C . D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy. Cancer Med. 2016; 5(10):2773-2780. PMC: 5083730. DOI: 10.1002/cam4.873. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

10.

Ho V, Jansen E, Wijnhoven B, Neelis K, van Sandick J, Verhoeven R . Adjuvant Chemoradiotherapy for Non-Pretreated Gastric Cancer. Ann Surg Oncol. 2017; 24(12):3647-3657. DOI: 10.1245/s10434-017-6048-3. View

11.

Perrot-Applanat M, Vacher S, Pimpie C, Chemlali W, Derieux S, Pocard M . Differential gene expression in growth factors, epithelial mesenchymal transition and chemotaxis in the diffuse type compared with the intestinal type of gastric cancer. Oncol Lett. 2019; 18(1):674-686. PMC: 6546989. DOI: 10.3892/ol.2019.10392. View

12.

Chu Y, Xu B, Song Q, Hu Q . Radiotherapy benefited the survival of patients with intestinal-type gastric adenocarcinoma: a SEER population-based study. Clin Transl Oncol. 2020; 23(1):164-171. DOI: 10.1007/s12094-020-02408-5. View

13.

Xu J, Zhu J, Wei Q . Adjuvant Radiochemotherapy versus Chemotherapy Alone for Gastric Cancer: Implications for Target Definition. J Cancer. 2019; 10(2):458-466. PMC: 6360300. DOI: 10.7150/jca.27335. View

14.

Ma G, Zhang H, Liu J, Chen Y, Xiao H, Wang X . Benefit of adjuvant chemoradiotherapy in patients with pathological stage III gastric cancer. Cancer Manag Res. 2019; 11:6029-6041. PMC: 6612289. DOI: 10.2147/CMAR.S204887. View

15.

Cats A, Jansen E, van Grieken N, Sikorska K, Lind P, Nordsmark M . Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncol. 2018; 19(5):616-628. DOI: 10.1016/S1470-2045(18)30132-3. View

16.

Lee J, Lim D, Kim S, Park S, Park J, Park Y . Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2011; 30(3):268-73. DOI: 10.1200/JCO.2011.39.1953. View

17.

Shridhar R, Almhanna K, Hoffe S, Fulp W, Weber J, Chuong M . Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: a Surveillance, Epidemiology, and End Results database analysis. Cancer. 2013; 119(9):1636-42. DOI: 10.1002/cncr.27927. View

18.

Macdonald J, Smalley S, Benedetti J, Hundahl S, Estes N, STEMMERMANN G . Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001; 345(10):725-30. DOI: 10.1056/NEJMoa010187. View